101
|
Moehler MH, Geissler M, Raedle J, Ebert M, Scherubl H, Flieger D, Seufferlein T, Galle P, Kanzler S. Erythropoetin (epoetin beta) once weekly in anemic patients with advanced cancer of the stomach or gastroesophageal junction: Interim results of a randomized German AIO phase II trail. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15133 Background: Tumor-related or chemotherapy-induced anemia is common in gastrointestinal cancer patients and results in reduced quality of life and worse prognosis. Thus, the effectiveness of erythropoetin (epoetin beta) treatment (EB) to achieve and maintain a target haemoglobin (Hb) level of ≥ 11 g/dl was assessed within a randomised German AIO phase II study to assess efficacy of irinotecan/capecitabine versus cisplatin/capecitabine in advanced gastric or lower esophageal cancer. Methods: Patients (pts) with untreated locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction (KPS ≥ 60%, > one measurable lesion, adequate organ functions) were randomized to receive 3-weekly cycles of either irinotecan 250 mg/m2 d1 (arm A) or cisplatin 80 mg/m2 d1 (arm B). Capecitabine was administered at 2000 mg/m2 for 14 days in both arms. In both arms, EB (30,000 I.E. once weekly) was given at Hb of < 11 g/dl and continued until Hb ≥ 12 g/dl. If after 4 treatment weeks, Hb increase was < 0.5 g/dl, EB was increased to 30,000 I.E. twice weekly. FACT-An questionnaires were completed at each cycle. Results: At time of abstract submission, 81 pts were randomized to A (37 pts) or B (44 pts). 23 pts received at least 3 EB injections (A: 10 pts, B: 13 pts). Median Hb prior to EB was 10.5 g/dl (A: 10.4 g/dl, B: 10.5 g/dl) and median Hb at end of EB was 11.6 g/dl (A: 11.5 g/dl, B: 11.75 g/dl). During EB, 80 % of A and 77 % of B achieved target Hb of ≥ 11 g/dl with a median rise in Hb of 2.0 g/dl (A: 1.4 g/dl, B: 2 g/dl). 5 pts in A and 7 pts in B responded with a ≥ 1 g/dl rise in Hb during first 4 weeks. FACT-An questionnaires showed no change from baseline to end of EB. Among evaluable pts with EB (20 pts) versus without EB (34 pts), response (CR + PR) and tumor control rates (CR + PR + SD) were 60% vs 35% and 85% vs 70%, respectively. Conclusions: EB is effective in raising Hb levels in advanced or metastatic gastric cancer. Patients receiving EB tend to show a better response to chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. H. Moehler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - M. Geissler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - J. Raedle
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - M. Ebert
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - H. Scherubl
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - D. Flieger
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - T. Seufferlein
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - P. Galle
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | - S. Kanzler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital Ulm, Ulm, Germany
| | | |
Collapse
|
102
|
Oettle H, Seufferlein T, Schmid R, Luger T, Ludwig S, Schmaus S, Wuerth G, Heinrichs H, Schlingensiepen K. Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- β2 inhibitor AP 12009. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4607] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4607 Background: TGF-β2 plays a pivotal role in tumor progression as it regulates key mechanisms, namely immunosuppression, metastasis, angiogenesis, and proliferation. The TGF-β2 inhibitor AP 12009 has shown clinical efficacy including complete and long-lasting remissions in patients with high-grade glioma. Methods: The currently ongoing clinical phase I/II study AP 12009-P001 is an open-label, multicenter, dose-escalation study. AP 12009 is being administered intravenously in adult patients with pancreatic carcinoma (PC, stage IVA/IVB), metastatic melanoma (MM, stage III/IV), or advanced colorectal carcinoma (CRC, stage III/IV). Primary endpoint is determination of the maximum tolerated dose (MTD). 3 to 6 patients per cohort (dose group) were enrolled into this dose escalation study. Results: So far, 17 patients have been treated in four dose groups, 11 patients with PC, 2 with MM, and 4 with CRC. Per cycle, AP 12009 was applied as a continuous i.v. infusion at weekly intervals in an out-patient setting. The 17 patients received one to ten cycles of AP 12009 (mean: 2.8). At the current stage, no (possibly) drug related serious adverse event (SAE), and only 17 (possibly) drug related adverse events (AEs) in eight patients have been observed. The 17 patients received one to ten cycles of AP 12009. Three dose-limiting toxicities (DLTs) occurred in the 4th dose group (exanthema grade 3 in one patient, thrombocytopenia grade 3 in two patients) and consequently, the MTD was determined as being 160 mg/m2/day with the current administration schedule. One patient suffering from MM stage IV is still alive 64 weeks after start of treatment. Moreover, one PC patient (stage IV) from the 2nd cohort is still after 72 weeks, having experienced a complete response. Further dose escalation studies in PC, MM, and CRC patients using a modified schedule are currently in preparation. Conclusions: In conclusion, encouraging case reports from the phase I/II study along with a good safety profile form a rational basis for the use of the TGF-β2 inhibitor AP 12009 as targeted therapy for advanced solid tumors such as PC, MM and CRC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Oettle
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - T. Seufferlein
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - R. Schmid
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - T. Luger
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - S. Ludwig
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - S. Schmaus
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - G. Wuerth
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - H. Heinrichs
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - K. Schlingensiepen
- Charite Campus Virchow Klinikum, Berlin, Germany; University of Ulm, Ulm, Germany; Klinikum rechts der Isar Tu München, Munich, Germany; University Hospital Münster, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| |
Collapse
|
103
|
Azoitei N, Brey A, Busch T, Fulda S, Adler G, Seufferlein T. Thirty-eight-negative kinase 1 (TNK1) facilitates TNFα-induced apoptosis by blocking NF-κB activation. Oncogene 2007; 26:6536-45. [PMID: 17471239 DOI: 10.1038/sj.onc.1210476] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Thirty-eight-negative kinase 1 (TNK1) is a member of the ACK-family of nonreceptor tyrosine kinases and was originally cloned from CD34+/Lin-/CD38-hematopoietic stem/progenitor cells. The signaling pathways induced by TNK1 are largely unknown. Here, we report that expression and consequent activation of TNK1 enables tumor necrosis factor alpha (TNFalpha)-induced apoptosis by selectively inhibiting TNFalpha-induced activation of nuclear factor-kappaB (NF-kappaB). TNK1 has no effect on NF-kappaB DNA binding or the composition of the NF-kappaB complex; however, the kinase markedly prevents TNFalpha-induced NF-kappaB transactivation. TNK1 therefore acts as a novel molecular switch that can determine the properties of TNFalpha signaling and therefore cell death.
Collapse
Affiliation(s)
- N Azoitei
- Department of Internal Medicine I, University of Ulm, and Children's Hospital, Ulm, Germany
| | | | | | | | | | | |
Collapse
|
104
|
|
105
|
Reinacher-Schick A, Arnold D, Lordick F, Möhler M, Lutz MP, Seufferlein T. [ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]. Z Gastroenterol 2006; 44:1065-72. [PMID: 17063436 DOI: 10.1055/s-2006-927142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review will give an overview on the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.
Collapse
Affiliation(s)
- A Reinacher-Schick
- Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
| | | | | | | | | | | |
Collapse
|
106
|
Oettle H, Seufferlein T, Schmid R, Luger T, Ludwig S, Schmaus S, Beyer M, Fischer D, Hafner M, Schlingensiepen K. Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009 for the treatment of advanced solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14012 Background: TGF-β overexpression in advanced tumors is correlated with tumor-induced immunosuppression, proliferation and angiogenesis. Furthermore, it is a key factor for induction of epithelial to mesenchymal transition (EMT), thus promoting invasion and metastasis. Targeted tumor therapy by an antisense oligonucleotide has already been proven to be successful in tumor therapy: AP 12009, a TGF-β2-mRNA-specific antisense oligodeoxynucleotide, has shown strong clinical indication of efficacy including complete and lasting remissions in malignant glioma. Methods: Spurred by the highly encouraging clinical data in malignant glioma and strong anti-tumor activity in a wide variety of preclinical assays, clinical studies in further indications were initiated. A multi-center dose-escalation phase I/II trial with AP 12009 in patients suffering from advanced solid tumors was started in 2005. Primary endpoint is to assess the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT). AP 12009 is administered i.v. in 14-day cycles. Results: Preclinically, in human pancreatic cancer and melanoma cell cultures AP 12009 significantly reduced the TGF-β2 secretion of cancer cells, inhibited tumor cell proliferation, and blocked migration of cancer cells. Additionally, AP 12009 reversed TGF-β2 mediated immunosuppression induced by pancreatic carcinoma cells. In the ongoing clinical phase I/II dose-escalation study, two cohorts of tumor patients have already been treated intravenously with AP 12009 as of Dec 2005. Further dose escalations are ongoing. So far, no DLT, no possibly related SAEs and only seven possibly related AEs were observed. MTD is not yet reached. The majority of patients received more than the minimum number of two cycles, one of them received ten full cycles. First signs of efficacy could also be observed. Conclusions: In conclusion, the preclinical results with pancreatic cancer and malignant melanoma cell cultures as well as the successful clinical application of AP 12009 in the lead indication malignant glioma form a rational basis for the use of the antisense compound AP 12009 as targeted therapy of advanced, TGF-β2 overexpressing tumors. [Table: see text]
Collapse
Affiliation(s)
- H. Oettle
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - T. Seufferlein
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - R. Schmid
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - T. Luger
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - S. Ludwig
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - S. Schmaus
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - M. Beyer
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - D. Fischer
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - M. Hafner
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| | - K. Schlingensiepen
- Charité Universitätsmedizin Berlin, Berlin, Germany; University of Ulm, Ulm, Germany; Technical University, Munich, Germany; Universitätsklinik, Münster, Germany; Antisense Pharma GmbH, Regensburg, Germany
| |
Collapse
|
107
|
Moehler M, Kanzler S, Geissler M, Raedle J, Ebert M, Scherubl H, Flieger D, Seufferlein T, Galle PR, Hoehler T. Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interim analysis of a randomized German AIO phase II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4032 Background: Irinotecan with 5-FU is highly effective in advanced gastric cancer. In addition, capecitabine seems to be as effective as 5-FU, with its advantage of oral administration. Thus, we compared efficacy and toxicity of irinotecan/capecitabine versus cisplatin/capecitabine in this prospective multicentric, open trail. Methods: Patients (pts) with previously untreated locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction and Karnofsky Performance status (KPS) of ≥ 60%, at least one measurable lesion and adequate organ functions were eligible. Pts were randomized to 3-weekly cycles of irinotecan 250 mg/m2, day 1 (arm A) or to cisplatin 80 mg/m2, day 1 (arm B). Capecitabine was administered at a 1000 mg/m2 twice daily for 14 days followed by a 7-day rest in both arms. Primary endpoint was remission rate, treatment was continued until disease progression. Results: At time of abstract submission, 91 of 120 pts (planned sample size) were randomized to arm A (45 pts) or B (46 pts). Interim data were available on 76 patients included into intent to treat analysis (34 pts arm A, 42 pts arm B). Baseline characteristics (arm A vs. B) were median age: 60 vs. 64 years, gender (female/male) 23%/77% vs. 30%/70%, KPS (≥80%) 97% vs. 93%, tumor distribution of gastric origin and gastroesophageal junction 85%/15% vs. 63%/37%. Grade 3 toxicities in A/B (% of pts) were anemia 3/9, neutropenia 17/19, diarrhoea 17/5, nausea 14/21, vomiting 3/14, hand-foot syndrome 6/2, respectively. Grade 4 toxicity occured only for neutropenia with 3% vs.5% in A/B, respectively. In 59 evaluable pts (28/31 in A/B), overall remission rate (CR + PR) and tumor control rate (CR + PR + SD) were 39% vs. 42% and 64% vs. 74%, respectively. Despite being only very descriptive, median progression-free and overall survival (arm A vs B) were 5.2 vs. 5.0 and 8.9 vs. 9.4 months, respectively. Conclusions: In patients with locally advanced or metastatic gastric and gastroesophageal cancer, both regimen irinotecan/capecitabine or cisplatin/capecitabine are effective, well tolerated and can be administered safely on an out-patient basis. Currently, both treatment arms are comparable. Accrual continues. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Moehler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - S. Kanzler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - M. Geissler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - J. Raedle
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - M. Ebert
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - H. Scherubl
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - D. Flieger
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - T. Seufferlein
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - P. R. Galle
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| | - T. Hoehler
- University of Mainz, Mainz, Germany; University of Freiburg, Freiburg, Germany; Saarland University, Homburg, Germany; University of Magdeburg, Magdeburg, Germany; Charité Campus Benjamin Franklin, Berlin, Germany; Klinikum Aschaffenburg, Aschaffenburg, Germany; University Hospital, Ulm, Germany; Prosper-Hospital Recklinghausen, Recklinghausen, Germany
| |
Collapse
|
108
|
Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6. [PMID: 16303861 DOI: 10.1093/annonc/mdj084] [Citation(s) in RCA: 192] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Twenty-one patients with untreated, metastatic, EGFR-expressing CRC received cetuximab 400 mg/m(2) as an initial dose, and thereafter 250 mg/m(2) weekly. In addition, patients received infusional 5-FU (24 h) in two dose levels (1500 mg/m(2), low 5-FU group, n = 6 or 2000 mg/m(2), high 5-FU group, n = 15), plus FA at 500 mg/m(2) and irinotecan at 80 mg/m(2), weekly x6 q50d. RESULTS Twenty patients were assessable for tolerability after the first cycle. There were no dose limiting toxicities (DLTs) in the low 5-FU group and three DLTs (20%) in the high 5-FU group (two patients with diarrhea grade 3 and one patient with diarrhea grade 4). In the low 5-FU group all six patients received >80% of the planned dose. In the high 5-FU group, seven of 14 patients (50%) received < or =80% of the planned chemotherapy dose during the first cycle due to dosage reductions whilst treatment delays occurred in 10/14 patients. During the whole study period, the common grade 3/4 adverse events were acne-like rash (38%) and diarrhea (29%). Chemotherapy did not affect the pharmacokinetics of cetuximab determined at weeks 1 and 4. Fourteen patients (67%, 95% CI 47% to 87%) had a confirmed response, and six (29%) had stable disease. Median time to progression was 9.9 months [lower 95% confidence limit (CL) 7.9, upper 95% CL not reached]. Median survival time was 33 months (lower CL 20, upper CL not reached). Four patients received secondary surgery with curative intent, and a fifth was potentially eligible for surgery but declined. CONCLUSIONS Addition of cetuximab to weekly infusional 5-FU/FA plus irinotecan is safe and first data suggest a promising activity. The 5-FU dose of 1500 mg/m(2) is recommended for further studies.
Collapse
|
109
|
Höhler T, Heike M, Lutz MP, Graeven U, Seufferlein T. [ASCO-Update 2005--Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005]. Z Gastroenterol 2005; 43:1253-9. [PMID: 16267711 DOI: 10.1055/s-2005-858746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review provides an overview of the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.
Collapse
Affiliation(s)
- T Höhler
- Prosper Hospital Recklinghausen, Recklinghausen
| | | | | | | | | |
Collapse
|
110
|
Seufferlein T. [Mechanisms of disease]. Z Gastroenterol 2005; 43:1111. [PMID: 16220449 DOI: 10.1055/s-2005-858669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
|
111
|
Arkenau HT, Schmoll H, Kubicka S, Kretzschmar A, Freier W, Seufferlein T, Graeven U, Grothey A, Hinke A, Porschen R. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3507] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H.-T. Arkenau
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - H. Schmoll
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - S. Kubicka
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - A. Kretzschmar
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - W. Freier
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - T. Seufferlein
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - U. Graeven
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - A. Grothey
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - A. Hinke
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| | - R. Porschen
- Hosp Bremen East, Bremen, Germany; Martin-Luther-University Halle, Halle, Germany; Medcl Sch Hannover, Hannover, Germany; Charité, Berlin, Germany; Private Oncology Clinic, Hildesheim, Germany; Univ Ulm, Ulm, Germany; Hosp Maria Hilf, Moenchengladbach, Germany; Mayo Clinic, Rochester, MN; Research Institute WISP Langenfeld, Langenfeld, Germany
| |
Collapse
|
112
|
Kaechele V, Seufferlein T, Höhler T, Möhler M, Lutz MP, Adler G. Oxaliplatin and paclitaxel in inoperable cancer of the esophagus and the gastro-esophogeal junction: Results of a phase I/II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V. Kaechele
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - T. Seufferlein
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - T. Höhler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - M. Möhler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - M. P. Lutz
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - G. Adler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| |
Collapse
|
113
|
Arnold D, Constantin C, Seufferlein T, Gahlemann CG, Schmoll HJ, Kretzschmar A. Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd- and/or 3rd-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3691] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Arnold
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - C. Constantin
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - T. Seufferlein
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - C. G. Gahlemann
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - H.-J. Schmoll
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - A. Kretzschmar
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| |
Collapse
|
114
|
Folprecht G, Lutz MP, Seufferlein T, Schoeffski P, Nolting A, Pollert P, Koehne CH. Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase I/IIa study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3640] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Folprecht
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| | - M. P. Lutz
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| | - T. Seufferlein
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| | - P. Schoeffski
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| | - A. Nolting
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| | - P. Pollert
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| | - C.-H. Koehne
- Univ Hosp Dresden, Dresden, Germany; Caritasklinik St. Theresia, Saarbruecken, Germany; Univ Hosp, Ulm, Germany; Catholic Univ Leuven, Leuven, Belgium; Merck KGaA, Darmstadt, Germany; Klin Oldenburg, Oldenburg, Germany
| |
Collapse
|
115
|
Seufferlein T, Dittrich C, Riemann J, Woell E, Herrmann T, Lordick F, Arnold D, Olchowka K, Hoehler T, Schmoll HJ. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3644] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Seufferlein
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - C. Dittrich
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - J. Riemann
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - E. Woell
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - T. Herrmann
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - F. Lordick
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - D. Arnold
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - K. Olchowka
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - T. Hoehler
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| | - H. J. Schmoll
- Univ Hosp, Ulm, Germany; LBI-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Vienna, Austria; Klin der Stadt, Ludwigshafen, Germany; Univ Hosp, Innsbruck, Austria; Univ Hosp, Heidelberg, Germany; Klin rechts der Isar der TU Muenchen, Munich, Germany; Martin-Luther-University Hosp, Halle, Germany; Merck KGaA, Darmstadt, Germany; Univ Hosp, Mainz, Germany
| |
Collapse
|
116
|
Abstract
With nearly 50 % of all colorectal cancers being diagnosed in patients at the age of 70 or above colorectal cancer is a disease of the elderly. In an adjuvant setting, fit elderly patients can receive the same benefit from cytotoxic therapy as younger patients with an only slightly increased toxicity. In a palliative setting, the treatment of elderly patients with respect to clinical endpoints such as response, time to progression or overall survival is as effective as in their younger counterparts. In clinical studies, older patients are generally underrepresented and among the elderly patients involved in clinical studies there is a bias towards particularly fit patients. Therefore it is not possible to extrapolate the results of many randomized trials to all elderly patients. A Comprehensive Geriatric Assessment (CGA) should be applied to detect the diversities in the geriatric population. Based on this assessment elderly patients classified as suitable for chemotherapy should be enrolled into clinical trials for colorectal cancer.
Collapse
Affiliation(s)
- V Kächele
- Abteilung Innere Medizin I, Universitätsklinikum Ulm
| | | | | | | |
Collapse
|
117
|
Suresh S, Spatz J, Mills JP, Micoulet A, Dao M, Lim CT, Beil M, Seufferlein T. Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria. Acta Biomater 2005; 1:15-30. [PMID: 16701777 DOI: 10.1016/j.actbio.2004.09.001] [Citation(s) in RCA: 448] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2004] [Revised: 09/02/2004] [Accepted: 09/02/2004] [Indexed: 10/26/2022]
Abstract
We investigate connections between single-cell mechanical properties and subcellular structural reorganization from biochemical factors in the context of two distinctly different human diseases: gastrointestinal tumor and malaria. Although the cell lineages and the biochemical links to pathogenesis are vastly different in these two cases, we compare and contrast chemomechanical pathways whereby intracellular structural rearrangements lead to global changes in mechanical deformability of the cell. This single-cell biomechanical response, in turn, seems to mediate cell mobility and thereby facilitates disease progression in situations where the elastic modulus increases or decreases due to membrane or cytoskeleton reorganization. We first present new experiments on elastic response and energy dissipation under repeated tensile loading of epithelial pancreatic cancer cells in force- or displacement-control. Energy dissipation from repeated stretching significantly increases and the cell's elastic modulus decreases after treatment of Panc-1 pancreatic cancer cells with sphingosylphosphorylcholine (SPC), a bioactive lipid that influences cancer metastasis. When the cell is treated instead with lysophosphatidic acid, which facilitates actin stress fiber formation, neither energy dissipation nor modulus is noticeably affected. Integrating recent studies with our new observations, we ascribe these trends to possible SPC-induced reorganization primarily of keratin network to perinuclear region of cell; the intermediate filament fraction of the cytoskeleton thus appears to dominate deformability of the epithelial cell. Possible consequences of these results to cell mobility and cancer metastasis are postulated. We then turn attention to progressive changes in mechanical properties of the human red blood cell (RBC) infected with the malaria parasite Plasmodium falciparum. We present, for the first time, continuous force-displacement curves obtained from in-vitro deformation of RBC with optical tweezers for different intracellular developmental stages of parasite. The shear modulus of RBC is found to increase up to 10-fold during parasite development, which is a noticeably greater effect than that from prior estimates. By integrating our new experimental results with published literature on deformability of Plasmodium-harbouring RBC, we examine the biochemical conditions mediating increases or decreases in modulus, and their implications for disease progression. Some general perspectives on connections among structure, single-cell mechanical properties and biological responses associated with pathogenic processes are also provided in the context of the two diseases considered in this work.
Collapse
Affiliation(s)
- S Suresh
- Department of Materials Science and Engineering, and Division of Bioengineering, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USA.
| | | | | | | | | | | | | | | |
Collapse
|
118
|
Graeven U, Heike M, Höhler T, Lutz MP, Messmann H, Seufferlein T, Eberl T. [ASCO update -- highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004]. Z Gastroenterol 2004; 42:1416-24. [PMID: 15592968 DOI: 10.1055/s-2004-813819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- U Graeven
- Krankenhaus St. Franziskus, Mönchengladbach
| | | | | | | | | | | | | |
Collapse
|
119
|
Arkenau HT, Schmoll HJ, Kubicka S, Seufferlein T, Reichardt P, Freier W, Graeven U, Grothey A, Porschen R. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim safety analysis. Z Gastroenterol 2004. [DOI: 10.1055/s-2004-831656] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
120
|
Arkenau HT, Schmoll H, Kubicka S, Seufferlein T, Reichardt P, Freier W, Graeven U, Grothey A, Porschen R. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H.-T. Arkenau
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - H. Schmoll
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - S. Kubicka
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - T. Seufferlein
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - P. Reichardt
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - W. Freier
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - U. Graeven
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - A. Grothey
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| | - R. Porschen
- Central Hospital Bremen East, Bremen, Germany; Martin-Luther-University-Halle, Halle, Germany; Medical School Hanover, Hanover, Germany; University Clinic Ulm, Ulm, Germany; Charité Berlin, Berlin, Germany; Private Oncology Clinic Hildesheim, Hildesheim, Germany; Ruhr-University-Bochum, Bochum, Germany; Mayo Clinic, Rochester, MN
| |
Collapse
|
121
|
Baust H, Schoke A, Brey A, Gern U, Los M, Schmid RM, Röttinger EM, Seufferlein T. Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-κB independent mechanisms. Oncogene 2003; 22:8786-96. [PMID: 14647473 DOI: 10.1038/sj.onc.1206969] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Radioresistance markedly impairs the efficacy of tumor radiotherapy and may involve antiapoptotic signal transduction pathways that prevent radiation-induced cell death. A common cellular response to genotoxic stress induced by radiation is the activation of the nuclear factor kappa B (NF-kappaB). NF-kappaB activation in turn can lead to an inhibition of radiation-induced apoptotic cell death. Thus, inhibition of NF-kappaB activation is commonly regarded as an important strategy to abolish radioresistance. Among other compounds, the fungal metabolite gliotoxin (GT) has been reported to be a highly selective inhibitor of NF-kappaB activation. Indeed, low doses of GT were sufficient to significantly enhance radiation-induced apoptosis in HL-60 cells. However, this effect turned out to be largely independent of NF-kappaB activation since radiation of HL-60 cells with clinically relevant doses of radiation induced only a marginal increase in NF-kappaB activity, and selective inhibition of NF-kappaB by SN50 did not result in a marked enhancement of GT-induced apoptosis. GT induced activation of JNKs, cytochrome c release from the mitochondria and potently stimulated the caspase cascade inducing cleavage of caspases -9, -8, -7 and -3. Furthermore, cleavage of the antiapoptotic protein X-linked IAP and downregulation of the G2/M-specific IAP-family member survivin were observed during GT-induced apoptosis. Finally, the radiation-induced G2/M arrest was markedly reduced in GT-treated cells most likely due to the rapid induction of apoptosis. Our data demonstrate that various other pathways apart from the NF-kappaB signaling complex can sensitize tumor cells to radiation and propose a novel mechanism for radiosensitization by GT, the interference with the G2/M checkpoint that is important for repair of radiation-induced DNA damage in p53-deficient tumor cells.
Collapse
Affiliation(s)
- H Baust
- Department of Radiation Oncology, University of Ulm, D-89081 Ulm, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
122
|
Eberl T, Graeven U, Heike M, Höhler T, Lutz MP, Messmann H, Seufferlein T. [ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003]. Z Gastroenterol 2003; 41:1039-45. [PMID: 14562203 DOI: 10.1055/s-2003-42922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- T Eberl
- Medizinische Klinik III, Klinikum Augsburg
| | | | | | | | | | | | | |
Collapse
|
123
|
Abstract
Major progress has been made in the treatment of metastatic colorectal cancer, but conventional chemotherapy is unlikely to lead to a major breakthrough in the treatment of gastrointestinal tumours. Prognosticators, novel means of early diagnosis of cancer which at the same time indicate prognosis, as well as novel, tumour-specific therapeutic strategies, are urgently needed. There is an increasing amount of promising data from array technology and functional proteomics suggesting that this goal could be achieved in the near future. Research into the mechanisms of cancer signal transduction over the past 20 years has enabled the identification of numerous novel targets for tumour therapy and subsequently the development of various novel drugs termed magic bullets. The in vitro results with these drugs are promising; many drugs lost their magic after the first clinical trials. The state of novel diagnostics and therapeutics in gastrointestinal cancer and the implications for the future treatment of these tumours are discussed in this review.
Collapse
Affiliation(s)
- T Seufferlein
- Department of Internal Medicine I, Medical University of Ulm, Germany.
| | | |
Collapse
|
124
|
Abstract
The detection of malignant cells in fine-needle aspirates (FNA's) using marker genes is hampered by the fact that these markers are only expressed by certain malignancies or lack sensitivity and/or specificity. Here we report the results of a prospective pilot study examining the expression of KOC (KH-domain containing protein over expressed in cancer), a novel onco-foetal gene, in 76 patients who underwent fine-needle aspiration for further diagnosis of abdominal lesions, aszites, cysts or cerebrospinal fluid. Aspirates were examined by cytology and by a KOC RT-PCR assay. KOC expression was a highly sensitive and specific indicator of malignancy. The KOC assay could be useful to facilitate screening for malignant disease and to improve the diagnostic accuracy of FNAs.
Collapse
Affiliation(s)
- F Mueller
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
| | - M Bommer
- Division of Hematology/Oncology, University of Ulm, Germany
| | - U Lacher
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
| | - C Ruhland
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
| | - V Stagge
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
| | - G Adler
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
| | - T M Gress
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
| | - T Seufferlein
- Division of Gastroenterology, Department of Medicine, University of Ulm, Germany
- Department of Internal Medicine I, Medical University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany. E-mail:
| |
Collapse
|
125
|
Seufferlein T, Lutz MP, Adler G. [Multimodal therapy in colon carcinoma]. Internist (Berl) 2003; 44:322-30, 332-5. [PMID: 12731419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Affiliation(s)
- T Seufferlein
- Abteilung Innere Medizin I, Universitätsklinikum Ulm.
| | | | | |
Collapse
|
126
|
Seufferlein T, Adler G. [Colon carcinoma--a preventable disease? Strategies for chemoprevention]. Z Gastroenterol 2002; 40 Suppl 2:79-83. [PMID: 12467019 DOI: 10.1055/s-2002-35886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- T Seufferlein
- Abt. Innere Medizin I, Medizinische Universitätsklinik Ulm
| | | |
Collapse
|
127
|
Seufferlein T, Seckl MJ, Schwarz E, Beil M, v Wichert G, Baust H, Lührs H, Schmid RM, Adler G. Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer 2002; 86:1188-96. [PMID: 11953870 PMCID: PMC2364182 DOI: 10.1038/sj.bjc.6600186] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2001] [Revised: 11/26/2001] [Accepted: 01/10/2002] [Indexed: 12/16/2022] Open
Abstract
Lipoxygenase metabolites of arachidonic acid can act as growth promoting factors for various cancer cell lines. Here we demonstrate that the 5-lipoxygenase inhibitor nordihydroguaiaretic acid potently inhibits anchorage-independent growth of human pancreatic and cervical cancer cells in soft agar and delays growth of pancreatic and cervical tumours established in athymic mice. Furthermore, nordihydroguaiaretic acid induces apoptosis of these cancer cells in vitro and in vivo. Potential mechanisms mediating these effects of nordihydroguaiaretic acid were examined. Nordihydroguaiaretic acid had no inhibitory effect on growth and survival signals such as tyrosine phosphorylation of the epidermal growth factor receptor or basal and growth factor-stimulated activities of extracellular signal-regulated kinase 1/2, p70(s6k) and AKT but selectively inhibited expression of cyclin D1 in the cancer cells. In addition, treatment with nordihydroguaiaretic acid lead to a disruption of the filamentous actin cytoskeleton in human pancreatic and cervical cancer cells which was accompanied by the activation of Jun-NH(2)-terminal kinase and p38(mapk). Similar effects were obtained by treatment of the cancer cells with cytochalasin D. These results suggest that nordihydroguaiaretic acid induces anoikis-like apoptosis as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases. In conclusion, nordihydroguaiaretic acid could constitute a lead compound in the development of novel therapeutic agents for various types of cancer.
Collapse
Affiliation(s)
- T Seufferlein
- Department of Internal Medicine I, University of Ulm, D-89081 Ulm, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
128
|
Poch B, Gansauge F, Schwarz A, Seufferlein T, Schnelldorfer T, Ramadani M, Beger HG, Gansauge S. Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression. Pancreas 2001; 23:280-7. [PMID: 11590324 DOI: 10.1097/00006676-200110000-00009] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
INTRODUCTION We recently showed that cyclin D1 is overexpressed in human pancreatic carcinoma cells, and that this overexpression correlates significantly with a poor prognosis. AIMS To assess the interrelations of epidermal growth factor (EGF), EGF receptor (EGFR), and cyclin D1 in human pancreatic carcinoma. METHODOLOGY AND RESULTS In pancreatic carcinoma cell lines (BxPC-3, AsPC-1), cell cycle analysis revealed an increase in cells in the S/G1 phase between 18 and 30 hours after stimulation with 50 ng/mL EGF. Cyclin D1 mRNA increased after 2 hours, corresponding to an increase in cyclin D1 protein, with the maximum level between 7.5 and 10 hours after stimulation, as demonstrated by Western blot analysis. We performed immunohistochemical analysis on 61 adenocarcinoma tissues for the expression of EGF, EGFR, and cyclin D1 and demonstrated an overexpression in the tumor cells in 51%, 54%, and 62.3%, respectively, whereas normal human pancreas stained negative for all of the three factors. Interestingly, EGF and EGFR expression correlated significantly with the cyclin D1 expression in human pancreatic tumor cells (p < 0.001 and p < 0.01, respectively). CONCLUSION These results demonstrate that cyclin D1 overexpression in the tumor cells of pancreatic carcinoma tissue is at least partly dependent on the mitogenic effects of EGF signaling through the EGFR.
Collapse
Affiliation(s)
- B Poch
- Department of General Surgery, University of Ulm, Germany
| | | | | | | | | | | | | | | |
Collapse
|
129
|
Stagge V, Seufferlein T, Duerschmied D, Dürschmied D, Menke A, Adler G, Beil M. Integrin-mediated differentiation of a pancreatic carcinoma cell line is independent of FAK or MAPK activation levels. Pancreas 2001; 23:236-45. [PMID: 11590318 DOI: 10.1097/00006676-200110000-00003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
INTRODUCTION The extracellular matrix (ECM) plays a salient role for proliferation and differentiation of epithelial cells. It was demonstrated that cell-ECM interactions mediated through integrins control gene expression and the tissue phenotype even in malignant tumors. Alterations of the ECM are a key feature of ductal adenocarcinoma of the pancreas. AIMS To examine the role of integrins and related signaling events for differentiation. METHODOLOGY AND RESULTS We established an in vitro model for ECM-induced differentiation of poorly differentiated pancreatic carcinoma cells and found that a specific pattern of ECM proteins resembling basal laminas (matrigel) induces differentiation of the PaTu-II pancreatic carcinoma cell line to a ductal phenotype. Both beta1- and beta4-integrins are required for cellular differentiation. Integrin-associated signaling events include activation of pp125 focal adhesion kinase (FAK) and mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinases (ERKs) and c-Jun NH2-terminal kinases (JNKs). However, beta1- and beta4-integrin-mediated differentiation of PaTu-II cells was independent from FAK, ERK, and JNK activation levels. Inhibition of MAPK kinases by PD98059 led to a reduction of proliferation but did not interfere with cellular differentiation of PaTu-II cells on matrigel. CONCLUSION The integrin-mediated differentiation of PaTu-II cells is regulated and maintained through FAK- and MAPK-independent signal transduction pathways.
Collapse
Affiliation(s)
- V Stagge
- Department of Internal Medicine I, University of Ulm, Germany
| | | | | | | | | | | | | |
Collapse
|
130
|
Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001; 61:4222-8. [PMID: 11358848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
The aim of this study was to examine the effects of transforming growth factor (TGF) beta1 on the phenotype and the biological behavior of pancreatic cancer cell lines with and without mutations in the TGF-beta signaling pathway and to elucidate whether the Ras signaling cascade participates in mediating these effects of TGF-beta1. TGF-beta-responsive (PANC-1, COLO-357, and IMIM-PC1) and nonresponsive (CAPAN1 and IMIM-PC2) pancreatic cancer cell lines with activating mutations of the Ki-Ras oncogene were treated with 10 ng/ml TGF-beta1 over time. Phenotypic alterations were studied by electron and phase contrast microscopy and by immunohistochemistry and expression analyses of differentiation markers. The influence of TGF-beta on tumor cell scattering, migration, and invasion was determined. The role of the Ras-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade in mediating TGF-beta-induced morphological and functional effects were studied by pretreatment with the MEK1 inhibitor PD 98059 and by measuring ERK2 activation using immune complex kinase assays. TGF-beta1 led to a reversible and time-dependent epithelial-mesenchymal transdifferentiation (EMT) in TGF-beta-responsive pancreatic cancer cell lines, characterized by a fibroblastoid morphology and an up-regulation of mesenchymal markers and a down-regulation of epithelial markers. EMT was associated with an increase in tumor cell migration, invasion, and scattering. In the responsive cell lines, TGF-beta1 induced a moderate but sustained activation of ERK2. EMT, the concomitant changes in gene expression, and the invasive and migratory potential were reduced or abolished by pretreatment with the selective MEK1 inhibitor. Thus, in TGF-beta-responsive pancreatic cancer cells with activating Ki-Ras mutations, TGF-beta1 treatment caused an EMT associated with a more invasive phenotype. Cross-talk with the Ras-MEK-ERK-signaling cascade appears to be essential for mediating these effects of TGF-beta1.
Collapse
Affiliation(s)
- V Ellenrieder
- Department of Internal Medicine I, University of Ulm, Robert-Koch-Strasse 8, D-89081 Ulm, Germany
| | | | | | | | | | | | | | | |
Collapse
|
131
|
Sturany S, Van Lint J, Muller F, Wilda M, Hameister H, Hocker M, Brey A, Gern U, Vandenheede J, Gress T, Adler G, Seufferlein T. Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem 2001; 276:3310-8. [PMID: 11062248 DOI: 10.1074/jbc.m008719200] [Citation(s) in RCA: 146] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have isolated the full-length cDNA of a novel human serine threonine protein kinase gene. The deduced protein sequence contains two cysteine-rich motifs at the N terminus, a pleckstrin homology domain, and a catalytic domain containing all the characteristic sequence motifs of serine protein kinases. It exhibits the strongest homology to the serine threonine protein kinases PKD/PKCmicro and PKCnu, particularly in the duplex zinc finger-like cysteine-rich motif, in the pleckstrin homology domain and in the protein kinase domain. In contrast, it shows only a low degree of sequence similarity to other members of the PKC family. Therefore, the new protein has been termed protein kinase D2 (PKD2). The mRNA of PKD2 is widely expressed in human and murine tissues. It encodes a protein with a molecular mass of 105 kDa in SDS-polyacrylamide gel electrophoresis, which is expressed in various human cell lines, including HL60 cells, which do not express PKCmicro. In vivo phorbol ester binding studies demonstrated a concentration-dependent binding of [(3)H]phorbol 12,13-dibutyrate to PKD2. The addition of phorbol 12,13-dibutyrate in the presence of dioleoylphosphatidylserine stimulated the autophosphorylation of PKD2 in a synergistic fashion. Phorbol esters also stimulated autophosphorylation of PKD2 in intact cells. PKD2 activated by phorbol esters efficiently phosphorylated the exogenous substrate histone H1. In addition, we could identify the C-terminal Ser(876) residue as an in vivo phosphorylation site within PKD2. Phosphorylation of Ser(876) of PKD2 correlated with the activation status of the kinase. Finally, gastrin was found to be a physiological activator of PKD2 in human AGS-B cells stably transfected with the CCK(B)/gastrin receptor. Thus, PKD2 is a novel phorbol ester- and growth factor-stimulated protein kinase.
Collapse
Affiliation(s)
- S Sturany
- Abteilung Innere Medizin I and Institut für Humangenetik, Medizinische Fakultät der Universität, Ulm, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
132
|
von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60:4573-81. [PMID: 10969809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Carcinoid tumors are predominantly found in the gastrointestinal tract and are characterized by hypersecretion of various substances, including bioamines and neuropeptides, leading to functional tumor disease. Here, we demonstrate that human BON carcinoid tumor cells express functionally active insulin-like growth factor-I (IGF-I) receptors and secrete IGF-I, suggesting an autocrine action of this growth factor. The IGF-I receptor was functionally active. IGF-I stimulated phosphatidylinositol 3-kinase (PI3-kinase), p70 S6 kinase (p70s6k), and extracellular signal-regulated kinase 2 activity in BON cells. Furthermore, immunoneutralization of endogenously released IGF-I markedly reduced the high basal activity of p70s6k and extracellular signal-regulated kinase 2 in serum-starved BON cells. Exogenously added IGF-I induced a marked increase in chromogranin A secretion, a marker protein for neuroendocrine secretion, by a process that was largely dependent on PI3-kinase activity. In addition, immunoneutralization of endogenously released IGF-I markedly reduced basal chromogranin A release by BON cells. Thus, the autocrine IGF-I loop regulates basal neuroendocrine secretion in BON cells. Next, we investigated the role of IGF-I as a growth promoting agent for BON cells. Our data demonstrate that IGF-I stimulates anchorage-dependent and anchorage-independent growth of BON cells by a pathway that involves PI3-kinase, mammalian target of rapamycin/p70s6k, and mitogen-activated protein kinase kinase 1 activity. Interestingly, mitogen-activated protein kinase kinase 1 activity was less important for anchorage-independent growth of BON cells. Endogenously released IGF-I was found to be largely responsible for autonomous growth of BON cells in serum-free medium and for the constitutive expression of cyclin D1 in these cells. In conclusion, IGF-I is a major autocrine regulator of neuroendocrine secretion and growth of human BON neuroendocrine tumor cells. Because our data also demonstrate that a significant proportion of neuroendocrine tumors express the IGF-I receptor and its ligand, interference with this pathway could be useful in the treatment of hypersecretion syndromes and growth of human neuroendocrine tumors.
Collapse
Affiliation(s)
- G von Wichert
- Department of Internal Medicine I, University of Ulm, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
133
|
Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59:3581-7. [PMID: 10446965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The FRAP-p70s6K signaling pathway was found to be constitutively phosphorylated/active in MiaPaCa-2 and Panc-1 human pancreatic cancer cells and a pancreatic cancer tissue sample as judged by the retarded electrophoretic mobility of the two major FRAP downstream targets, p70s6K and 4E-BP1. Treatment of cells with rapamycin, a selective FRAP Inhibitor, inhibited basal p70s6K kinase activity and induced dephosphorylation of p70s6K and 4E-BP1. Moreover, rapamycin inhibited DNA synthesis as well as anchorage-dependent and -independent proliferation in MiaPaCa-2 and Panc-1 cells. Finally, rapamycin strikingly inhibited cyclin D1 expression in pancreatic cancer cells. Thus, inhibitors of the constitutively active FRAP-p70s6K pathway may provide a novel therapeutic approach for pancreatic cancer.
Collapse
Affiliation(s)
- M Grewe
- Department of Internal Medicine I, University of Ulm, Germany
| | | | | | | | | |
Collapse
|
134
|
Abstract
BACKGROUND & AIMS The aim of this study was to identify signaling pathways that mediate cell proliferation in response to a Ras-activating growth factor, transforming growth factor (TGF)-alpha, in two pancreatic cancer cell lines with constitutively active Ki-Ras, MiaPaCa-2, and Panc-1. METHODS ERK1/-2- and p90(rsk) activation were determined by immune complex kinase assays. AP-1 and E74 activation were assessed in transient transfections using luciferase reporter plasmids. Ha-Ras activation was determined using a glutathione S-transferase fusion protein comprising the Ras-binding domain of Raf and by immunocytochemistry, growth by DNA synthesis and colony formation in softagar. RESULTS TGF-alpha stimulated activation of ERK1/-2, which was dependent on MEK-1, but independent of PKC activity. TGF-alpha-induced activation of an AP-1 reporter plasmid also required MEK-1 and Ras activity. Using an E74 reporter plasmid, we demonstrate that TGF-alpha indeed activates Ras in both cell lines. In particular, TGF-alpha induced membrane translocation and activation of the Ras isoform Ha-Ras. Finally, TGF-alpha-stimulated DNA synthesis and clonal growth in soft agar were prevented by treatment of cells with a MEK-1 inhibitor or a Ras farnesyl transferase inhibitor. CONCLUSIONS The Ha-Ras-ERK cascade plays an important role in TGF-alpha-induced growth of pancreatic cancer cells with activating Ki-ras mutations. Inhibitors of this cascade could constitute novel anticancer agents for pancreatic tumors.
Collapse
Affiliation(s)
- T Seufferlein
- Department of Internal Medicine I, University of Ulm, Ulm, Germany.
| | | | | | | | | |
Collapse
|
135
|
Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJ, Daniel S, Schwarz J. Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport 1998; 9:3029-32. [PMID: 9804310 DOI: 10.1097/00001756-199809140-00020] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Microglial activation is a prominent feature of affected brain areas in multiple system atrophy. Microglia express proinflammatory peptides, which may be a result of activation of nuclear factor-KB. We investigated the nuclear presence of RelA, the 65 kDa subunit of the NF-KB/RelA family in striatum and brain stem of patients with multiple system atrophy. Affected brain areas of patients with multiple system atrophy showed a marked immunoreactivity for nuclear Rel A p65, which was almost exclusively localized in activated microglia. Interestingly nuclear translocation of Rel A was not detected in striatal tissue of controls and Parkinson disease patients. Thus, NF-kappaB/Rel A complexes may play a role in mediating microglial activation in multiple system atrophy.
Collapse
Affiliation(s)
- S C Schwarz
- Department of Neurology, University of Ulm, Germany
| | | | | | | | | | | | | | | |
Collapse
|
136
|
Gansauge S, Gansauge F, Yang Y, Müller J, Seufferlein T, Ramadani M, Beger HG. Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas. Cancer Res 1998; 58:2703-6. [PMID: 9661876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We investigated the expression of interleukin 1beta-converting enzyme (ICE; caspase-1) in human adenocarcinomas of the pancreas. Immunohistochemistry and Western blot analyses revealed an overexpression of ICE in 71 and 80% of tumor cells, respectively. Also, on a mRNA level, ICE mRNA was overexpressed in 45% of the cases, as compared to normal pancreatic tissue. Interestingly, the overexpression of ICE in tumor cells correlated significantly with the overexpression of cyclin D1, epidermal growth factor, and epidermal growth factor receptor (P < 0.0005, P < 0.05, and P < 0.002, respectively), which are involved in cell cycle progression and proliferation in human pancreatic carcinoma. This is the first report concerning ICE expression in human carcinomas; however, the exact mechanism underlying these close correlations warrant further research.
Collapse
Affiliation(s)
- S Gansauge
- Department of General Surgery, University of Ulm, Germany
| | | | | | | | | | | | | |
Collapse
|
137
|
Withers DJ, Seufferlein T, Mann D, Garcia B, Jones N, Rozengurt E. Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells. J Biol Chem 1997; 272:2509-14. [PMID: 8999966 DOI: 10.1074/jbc.272.4.2509] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Phosphorylation and subsequent activation of p70 S6 kinase (S6K) are events that are highly conserved in the cellular response to mitogens. The neuropeptide bombesin, which is a potent mitogen for Swiss 3T3 cells, stimulated a time- and dose-dependent activation of p70(S6K) as determined by gel mobility shift and immune complex kinase assays. This effect was inhibited by the immunosuppressant rapamycin at 10 nM, which also completely abolished bombesin-stimulated DNA synthesis at identical concentrations. In striking contrast, the combination of bombesin and insulin in synergy stimulated maximum DNA synthesis in these cells despite persistent inhibition of p70(S6K) by rapamycin throughout G1. These results indicate that activation of p70(S6K) is not required for the transition of quiescent cells to the S phase of the cell cycle. The inhibitory effects of rapamycin on bombesin-stimulated cell cycle progression did not involve accumulation of the cyclin-dependent kinase inhibitor p27(kip1) but a striking inhibition of the expression of cyclin D1. This effect was circumvented by bombesin with insulin, suggesting that a rapamycin-insensitive pathway stimulated by this combination leads to cyclin D1 expression. Thus, these findings, dissociating the mitogenic effects of bombesin in synergy with insulin from activation of p70(S6K), support the hypothesis that this kinase is a component of one of the parallel pathways that can lead to DNA synthesis rather than an obligatory point of convergence in mitogenic signaling.
Collapse
Affiliation(s)
- D J Withers
- Imperial Cancer Research Fund, P. O. Box 123, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom
| | | | | | | | | | | |
Collapse
|
138
|
Abstract
The majority of cases of central diabetes insipidus are still pathogenetically unclear (idiopathic). Atherosclerotic cholesterol emboli might be partly responsible for some of these idiopathic cases. A 54-year-old woman with known aortic valve stenosis and a history of a transitory ischemic attack presented with sudden-onset polyuria and polydipsia of up to eight l/d, which had started acutely with headaches. She had been treated with lithium for 3 years because of cyclothymic depression. Plasma sodium was in the upper normal range (142-148 mmol/l). Hypertonic saline infusion during lithium therapy revealed a normal threshold of thirst and resetting of vasopressin secretion (osmotic threshold > 300 mosmol/l), whereas vasopressin reserve was normal. Lithium withdrawal led to an even greater delay of vasopressin release upon hypertonic saline infusion (> 310 mosmol/l). Pituitary function tests revealed a normal anterior pituitary function. MR imaging of the hypothalamo-hypophyseal region showed a normal hypothalamic region and a highly intensive neurohypophyseal signal in the T1-weighted image. The patient responded well to desmopressin. We suggest that in this rare case clinical symptoms as well as biochemical findings like impairment of AVP release might be related to a minor structural hypothalamic damage by a vascular lesion, caused, for example, by an atheromatous (cholesterol) embolism in the hypothalamic region responsible for integration of osmoreceptor function and AVP-secretion. The patient's atherosclerosis and aortic stenosis might be responsible for this event.
Collapse
Affiliation(s)
- J Hensen
- Department of Internal Medicine, Benjamin Franklin Hospital, Freie Universität Berlin, Germany.
| | | | | |
Collapse
|
139
|
Seufferlein T, Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 1996; 56:5758-64. [PMID: 8971188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Addition of phorbol 12,13-dibutyrate (PDB) to H 69, H 345, and H 510 small cell lung cancer (SCLC) cells led to a rapid concentration- and time-dependent increase in p42mapk activity. PD 098059 [2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one], a selective inhibitor of mitogen activated protein kinase (MAPK) kinase 1, prevented activation of p42mapk by PDB in SCLC cells. PDB also stimulated the activation of p90rsk, a major downstream target of p42mapk. The effect of PDB on both p42mapk and p90rsk activation could be prevented by down-regulation of protein kinase C (PKC) by prolonged pretreatment with 800 nM PDB or treatment of SCLC cells with the PKC inhibitor bisindolylmaleimide (GF 109203X), demonstrating the involvement of phorbol ester-sensitive PKCs in the signaling pathway leading to p42mapk activation. Various neuropeptides, such as bradykinin, vasopressin, bombesin, neurotensin, and galanin, which promote clonal growth in SCLC cells, also induced activation of p42mapk in these cells. In particular, galanin and neurotensin stimulated p42mapk activation in SCLC cells by a pathway that was dependent on the activity of PKC. Furthermore, galanin-stimulated clonal growth of SCLC cells in semisolid medium could be prevented by the PKC inhibitor GF 109203X and by PD 098059. Thus, our results suggest that activation of p42mapk plays an important role in neuropeptide-induced growth of SCLC.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | |
Collapse
|
140
|
Seufferlein T, Withers DJ, Mann D, Rozengurt E. Dissociation of mitogen-activated protein kinase activation from p125 focal adhesion kinase tyrosine phosphorylation in Swiss 3T3 cells stimulated by bombesin, lysophosphatidic acid, and platelet-derived growth factor. Mol Biol Cell 1996; 7:1865-75. [PMID: 8970151 PMCID: PMC276036 DOI: 10.1091/mbc.7.12.1865] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
The experiments presented here were designed to examine the contribution of p125 focal adhesion kinase (p125FAK) tyrosine phosphorylation to the activation of the mitogen-activated protein kinase cascade induced by bombesin, lysophosphatidic acid (LPA), and platelet-derived growth factor (PDGF) in Swiss 3T3 cells. We found that tyrosine phosphorylation of p125FAK in response to these growth factors is completely abolished in cells treated with cytochalasin D or in cells that were suspended in serum-free medium for 30 min. In marked contrast, the activation of p42mapk by these factors was independent of the integrity of the actin cytoskeleton and of the interaction of the cells with the extracellular matrix. The protein kinase C inhibitor GF 109203X and down-regulation of protein kinase C by prolonged pretreatment of cells with phorbol esters blocked bombesin-stimulated activation of p42mapk, p90rsk, and MAPK kinase-1 but did not prevent bombesin-induced tyrosine phosphorylation of p125FAK. Furthermore, LPA-induced p42mapk activation involved a pertussis toxin-sensitive guanylate nucleotide-binding protein, whereas tyrosine phosphorylation of p125FAK in response to LPA was not prevented by pretreatment with pertussis toxin. Finally, PDGF induced maximum p42mapk activation at concentrations (30 ng/ml) that failed to induce tyrosine phosphorylation of p125FAK. Thus, our results demonstrate that p42mapk activation in response to bombesin, LPA, and PDGF can be dissociated from p125FAK tyrosine phosphorylation in Swiss 3T3 cells.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | | | | | |
Collapse
|
141
|
Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996; 56:3895-7. [PMID: 8752154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The serine/threonine kinase p70s6k was found to be constitutively phosphorylated in H 69, H 345, and H 510 small cell lung cancer cells as judged by the retarded electrophoretic mobility of both isoforms of this kinase. Pretreatment of H 69, H 345, and H 510 cells with the potent immunosuppressant rapamycin led to p70s6k dephosphorylation in a concentration-dependent manner; half-maximum and maximum effects were achieved at 0.3 and 3 nM rapamycin, respectively. Rapamycin inhibited growth of H 69, H 345, and H 510 cells in liquid culture at similar concentrations to those required for inducing dephosphorylation of p70s6k. Furthermore, rapamycin markedly reduced the basal colony forming ability of H 69, H 345, and H 510 cells in semisolid media. Thus, constitutively phosphorylated/active p70s6k plays an important role in promoting the growth of small cell lung cancer cells. Furthermore, the rapamycin-sensitive p70s6k pathway may provide a novel target for therapeutic intervention in small cell lung cancer.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | |
Collapse
|
142
|
Seufferlein T, Withers DJ, Rozengurt E. Reduced requirement of mitogen-activated protein kinase (MAPK) activity for entry into the S phase of the cell cycle in Swiss 3T3 fibroblasts stimulated by bombesin and insulin. J Biol Chem 1996; 271:21471-7. [PMID: 8702930 DOI: 10.1074/jbc.271.35.21471] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Bombesin induced a marked and persistent activation of the mitogen-activated protein kinase kinase-1 (MEK-1), p42(mapk) and p90(rsk) in Swiss 3T3 cells by a pathway that was independent of p74(raf-1) but dependent on the activity of protein kinase C. Pretreatment of the cells with a specific inhibitor of MEK-1, PD 098059, markedly reduced the early and abolished the sustained phase of bombesin-induced p42(mapk) activation. In addition, PD 098059 prevented bombesin-induced DNA synthesis and progression of the cells through the cell cycle, indicating that the mitogenic effect of bombesin is dependent on the activation of p42(mapk). However, in the presence of insulin, which neither stimulated p42(mapk) activation nor DNA synthesis on its own in Swiss 3T3 cells, bombesin potently stimulated DNA synthesis even at concentrations of PD 098059 (15 microM) that completely abolished the mitogenic effect of bombesin alone. Furthermore, Swiss 3T3 cells stably transfected with interfering mutants of MEK-1 showed a marked decrease in the mitogenic effect of bombesin. In contrast, the combination of bombesin and insulin strongly stimulated DNA synthesis in these cells to levels comparable with that obtained in the wild type cells. Thus, our data demonstrate that insulin dramatically reduced the requirement for the mitogen-activated protein kinase pathway for reinitiation of DNA synthesis in bombesin-treated Swiss 3T3 cells and consequently indicate that the contribution of the mitogen-activated protein kinase cascade to mitogenesis depends on the combination of extracellular signals that are used to stimulate these cells.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, P. O. Box 123, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom
| | | | | |
Collapse
|
143
|
Withers DJ, Coppock HA, Seufferlein T, Smith DM, Bloom SR, Rozengurt E. Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett 1996; 378:83-7. [PMID: 8549809 DOI: 10.1016/0014-5793(95)01427-6] [Citation(s) in RCA: 105] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Our results demonstrate that the novel vasoactive regulatory peptide adrenomedullin is a potent mitogen for Swiss 3T3 cells. Acting via a specific adrenomedullin receptor, it stimulates a dose-dependent increase in DNA synthesis in synergy with insulin. Additionally, adrenomedullin stimulates further progression through the cell cycle resulting in cell proliferation, an effect that was further enhanced by the presence of insulin. Adrenomedullin rapidly induces accumulation of intracellular cAMP but does not stimulate an increase in intracellular Ca2+, activation of protein kinase C, or tyrosine phosphorylation of intracellular substrates. Adrenomedullin-stimulated mitogenesis is markedly enhanced in Swiss 3T3 cells stably transfected with a constitutively activated Gs alpha, which are highly sensitive to agents that elevate cAMP, and is inhibited by the PKA inhibitor H-89. Adrenomedullin is, thus, identified as a novel mitogenic regulatory peptide acting via cAMP.
Collapse
|
144
|
Seufferlein T, Rozengurt E. Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein. J Biol Chem 1995; 270:24334-42. [PMID: 7592645 DOI: 10.1074/jbc.270.41.24334] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Sphingosylphosphorylcholine (SPC) is a potent mitogen for Swiss 3T3 cells, but the signaling mechanisms involved are poorly characterized. Here, we report that addition of SPC induces a rapid and transient activation of p42 mitogen-activated protein kinase (p42MAPK) in these cells. SPC-induced p42MAPK activation peaked at 5 min and was undetectable after 30 min of incubation with SPC. The effect of SPC on p42MAPK activation was comparable to that induced by bombesin and platelet-derived growth factor. As SPC strongly induced phosphorylation of the major protein kinase C (PKC) substrate 80K/MARCKS in either intact or permeabilized cells, we examined whether PKC could be involved in SPC-induced p42MAPK activation. Here, we demonstrate that p42MAPK activation by SPC was dependent on PKC activity as shown by inhibition of PKC with the bisindolymaleimide GF 109203X or down-regulation of PKC by prolonged treatment of Swiss 3T3 cells with phorbol esters. Activation of both PKC and p42MAPK by SPC was markedly inhibited by treatment with pertussis toxin, implicating a G proteins(s) of the Gi/G(o) subfamily in the action of SPC. SPC-induced rapid activation of a downstream target of p42MAPK, p90 ribosomal S6 kinase (p90rsk), also required PKC and a pertussis toxin-sensitive G protein. In addition, SPC-induced mitogenesis was dependent on a Gi protein in Swiss 3T3 cells. SPC also induced p42MAPK activation and DNA synthesis in secondary cultures of mouse embryo fibroblasts through a pertussis toxin-sensitive pathway. As G proteins link many cell surface receptors to effector proteins, we hypothesize, therefore, that SPC could bind to a receptor that mediates at least some of its biological effects in Swiss 3T3 cells and mouse embryo fibroblasts.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | |
Collapse
|
145
|
Seufferlein T, Rozengurt E. Sphingosylphosphorylcholine rapidly induces tyrosine phosphorylation of p125FAK and paxillin, rearrangement of the actin cytoskeleton and focal contact assembly. Requirement of p21rho in the signaling pathway. J Biol Chem 1995; 270:24343-51. [PMID: 7592646 DOI: 10.1074/jbc.270.41.24343] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Sphingosylphosphorylcholine (SPC), a potent mitogen for Swiss 3T3 cells, rapidly induced tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000 in Swiss 3T3 cells. Focal adhesion kinase (p125FAK) and paxillin were identified as prominent substrates for SPC-stimulated tyrosine phosphorylation. An increase in tyrosine phosphorylation of p125FAK was detected as soon as 30 s after SPC stimulation, reaching a maximum after 2.5 min. SPC induced tyrosine phosphorylation of p125FAK in a concentration-dependent fashion; a half-maximum effect occurred at 250 nM. Tyrosine phosphorylation of p125FAK induced by SPC could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores. SPC induced a unique pattern of reorganization of the actin cytoskeleton with a rapid appearance of actin microspikes at the plasma membrane that was followed by the formation of actin stress fibers. This pattern of cytoskeletal changes was clearly distinguishable from that induced by bombesin and 1-oleoyl-lysophosphatidic acid. Formation of microspikes and actin stress fibers were accompanied by striking assembly of focal adhesion plaques. Cytochalasin D, which disrupts the network of actin microfilaments, completely prevented SPC-induced tyrosine phosphorylation of p125FAK. In addition, tyrosine phosphorylation of p125FAK was markedly inhibited in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that disrupts actin stress fibers. Finally, microinjection of Clostridium botulinum C3 exoenzyme, which inactivates p21rho, prevented SPC-induced formation of actin stress fibers, focal adhesion assembly, and tyrosine phosphorylation. Thus, p21rho is upstream of both cytoskeletal reorganization and tyrosine phosphorylation in SPC-treated cells.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | |
Collapse
|
146
|
Seufferlein T, Withers DJ, Broad S, Herget T, Walsh JH, Rozengurt E. The human CCKB/gastrin receptor transfected into rat1 fibroblasts mediates activation of MAP kinase, p74raf-1 kinase, and mitogenesis. Cell Growth Differ 1995; 6:383-93. [PMID: 7794806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The human cholecystokinin (CCK)B/gastrin receptor was stably transfected into Rat1 fibroblasts to examine the signaling pathways mediated by this seven-transmembrane, G protein-linked receptor. We report here that binding of CCK-8 or gastrin to the CCKB/gastrin receptor induced phosphoinositide breakdown and led to a rapid, transient, and concentration-dependent increase in intracellular Ca2+, which was completely blocked by a specific CCKB receptor antagonist. The peptides also stimulated tyrosine phosphorylation of focal adhesion kinase (p125FAK) and paxillin. Both CCK-8 and gastrin induced a dose- and time-dependent activation of MAP kinase and p74raf-1 kinase in the transfected Rat1 cells. These effects could be dissociated from protein kinase C activation and were not dependent on a functional Gi protein. Finally, both CCK-8 and gastrin induced DNA synthesis in Rat1 cells transfected with the human CCKB/gastrin receptor through a pertussis toxin-insensitive pathway. These results indicate that the neuropeptides gastrin and CCK can activate multiple signal transduction pathways and act as sole mitogens by binding to the CCKB/gastrin receptor transfected into Rat1 fibroblasts.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
147
|
Seckl MJ, Seufferlein T, Rozengurt E. Lysophosphatidic acid-depleted serum, hepatocyte growth factor and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway. Cancer Res 1994; 54:6143-7. [PMID: 7525056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Serum stimulates both Ca2+ mobilization and colony growth of many small cell lung cancer (SCLC) cell lines, but the factors involved remain unknown. We demonstrate that 1-oleoyl-lysophosphatidic acid (LPA), like serum, induced a dose-dependent increase in intracellular Ca2+ in the H-510, H-345, and H-69 SCLC cell lines with half maximal concentrations of 18 nM, 22 nM, and 20 nM, respectively. Two lines of evidence revealed that LPA was the major factor in serum responsible for mobilizing Ca2+ in these SCLC cell lines: (a) both LPA and serum exhibited cross desensitization in the Ca2+ mobilization assay; and (b) phospholipase B pretreatment of either LPA or serum prevented the ability of these agents to stimulate Ca2+ mobilization. In marked contrast, LPA at concentrations between 2 nM and 20 microM, unlike serum, failed to stimulate colony formation. Furthermore, phospholipase B treatment of serum did not inhibit serum-induced colony formation. We therefore searched for growth factors which could induce colony growth through a Ca(2+)-independent pathway. We found that both human recombinant hepatocyte growth factor and stem cell growth factor increased colony growth, but failed to stimulate an increase in intracellular Ca2+ in the H-510, H-345, and H-69 SCLC cell lines. Our results indicate that LPA-depleted serum, hepatocyte growth factor, and stem cell growth factor stimulate colony formation in SCLC cells through a Ca(2+)-independent pathway.
Collapse
Affiliation(s)
- M J Seckl
- Imperial Cancer Research Fund, London, United Kingdom
| | | | | |
Collapse
|
148
|
Seufferlein T, Rozengurt E. Sphingosine induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. J Biol Chem 1994; 269:27610-7. [PMID: 7525558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Treatment of Swiss 3T3 cells with sphingosine, a potential breakdown product of all sphingolipids, induced tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. Tyrosine phosphorylation in response to sphingosine occurred in a concentration dependent manner (EC50 = 10 microM) and developed gradually reaching half maximum and maximum effects at 20 and 60 min, respectively. The dihydroenantiomere of sphingosine, DL-threo-dihydrosphingosine, neither induced tyrosine phosphorylation nor interfered with sphingosine-stimulated tyrosine phosphorylation. Focal adhesion kinase (p125FAK) and paxillin were identified as prominent substrates for sphingosine-stimulated tyrosine phosphorylation. Cell permeable ceramides also stimulated tyrosine phosphorylation of the M(r) 110,000-130,000 band as well as p125FAK, but the effect was less pronounced than that of sphingosine. Tyrosine phosphorylation by sphingosine could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores. Sphingosine stimulated striking actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells. The kinetics of actin stress fiber formation and tyrosine phosphorylation in response to sphingosine closely paralleled. Cytochalasin D, which disrupts the network of actin microfilaments, completely inhibited sphingosine induced tyrosine phosphorylation. In addition, tyrosine phosphorylation of p125FAK and paxillin in response to sphingosine was completely prevented when cells were stimulated in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that caused disruption of the actin cytoskeleton. Our results demonstrate, for the first time, that sphingosine induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | |
Collapse
|
149
|
Seufferlein T, Rozengurt E. Sphingosine induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. J Biol Chem 1994. [DOI: 10.1016/s0021-9258(18)47028-7] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
150
|
Seufferlein T, Rozengurt E. Lysophosphatidic acid stimulates tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130. Signaling pathways and cross-talk with platelet-derived growth factor. J Biol Chem 1994; 269:9345-51. [PMID: 7510708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Addition of 1-oleoyl-lysophosphatidic acid (LPA) induces tyrosine phosphorylation of multiple substrates in Swiss 3T3 cells including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. An increase in tyrosine phosphorylation of the M(r) 110,000-130,000 cluster of bands was detected as soon as 30 s after LPA stimulation reaching a maximum within 1 min. LPA stimulated tyrosine phosphorylation of all bands in a concentration-dependent fashion; a half-maximal effect occurred at 30 nM. Immunoprecipitation of lysates of LPA-treated cells with monoclonal antibodies that specifically recognize focal adhesion kinase (p125FAK), paxillin, and p130 revealed that these proteins are prominent substrates for LPA-stimulated tyrosine phosphorylation. Down-regulation of protein kinase C (PKC) by prolonged pretreatment with phorbol 12,13-dibutyrate, selective inhibition of PKC by GF109203X, or depletion of the intracellular Ca2+ pool by thapsigargin had no effect on LPA-stimulated tyrosine phosphorylation. Thus, protein tyrosine phosphorylation by LPA is largely independent of either the PKC or Ca2+ pathways. In contrast, pretreatment of the cells with cytochalasin D, which selectively disrupts the network of the actin filaments, completely inhibited LPA-induced tyrosine phosphorylation. Furthermore, tyrosine phosphorylation of p125FAK induced by LPA was completely prevented when cells were stimulated in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that causes disruption of actin stress fibers. This suggests that the integrity of the actin cytoskeleton is essential for LPA-induced tyrosine phosphorylation and reveals a novel cross-talk between LPA and platelet-derived growth factor on p125FAK tyrosine phosphorylation.
Collapse
Affiliation(s)
- T Seufferlein
- Imperial Cancer Research Fund, London, United Kingdom
| | | |
Collapse
|